Učitavanje...
Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC
Lung cancer is the leading cause of cancer death in the US with ∼124,000 new cases annually, and a 5 y survival rate of ∼16%. Mutant KRAS-driven lung adenocarcinoma (KRAS LADC) is a particularly prevalent and deadly form of lung cancer. Protein kinase Cι (PKCι) is an oncogenic effector of KRAS that...
Spremljeno u:
| Izdano u: | Small GTPases |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331898/ https://ncbi.nlm.nih.gov/pubmed/27245608 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21541248.2016.1194953 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|